ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2156

Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome

Qingping Yao1 and Apostolos Kontzias 1, 1Stony Brook University, Stony Brook, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Autoinflammatory Disease, Eye disease, genetics and Yao syndrome, NOD2

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Yao syndrome (YAOS, OMIM 617321), formerly termed nucleotide-binding, oligomerization domain 2(NOD2)-associated autoinflammatory disease, has become increasingly recognized. The disease has been reported in America, Europe and Asia, and seems not uncommon.  This study aimed to report novel phenotypic and genotypic findings in the disease.

Methods: This is a retrospective review of electronic medical records (EMRs) of 11 patients with YAOS, and the study was approved by the Stony Brook University (SBU) Institutional Research Board.  These patients after an extensive workup without a unified diagnosis were referred to our Center of Autoinflammatory Disease at SBU, and followed up, and the charts were well documented by the lead author who has a vested interest in the disease. All these patients underwent genetic testing for periodic fever syndrome 6-gene panel (MEFV, TNFRSF1A, NLRP3, MVK, NLRP12 and NOD2) or targeted gene sequencing for NOD2. These patients were included in the study because they fulfilled the diagnostic criteria for YAOS and had either eyelid swelling as corroborated by i-phone photographs and/or NOD2 variants that were not identified previously for the disease. Continuous variables were expressed as median, interquartile range, and frequency for descriptive statistics.

Results: All YAOS patients (10 females, 1 male) were Caucasians with the mean age of 25.9 at disease onset. They shared such known common phenotype for YAOS as fever, rash, arthritis/arthralgia, gastrointestinal, and sicca-like symptoms (Table 1). Three patients had a family history of the similar symptoms.  Of note, 7 of the 11 patients developed unilateral or bilateral eyelid swelling with or without discoloration or eye redness (Figure 1). The symptom recurred and concurred with other clinical manifestations during disease flares and each episode lasted several hours to a few days with resolution. Six of the 7 patients carry the common NOD2 variants associated with YAOS. Of the 11 patients, 5 patients had clinical characteristics of YAOS and carry the rare NOD2 variants. These data support eyelid swelling as a new clinical feature of YAOS, and the spectrum of NOD2 variants associated with YAOS is extended.

Conclusion: This study indicates that the eyelid swelling and rare NOD2 variants are added clinical and genetic characteristics of YAOS. Recognition of the expanded disease spectrum will foster prompt diagnosis and management of the disease.


Table 1final

Table 1. Baseline Demographics, Clinical and Laboratory Characteristics of YAOS Patients

Eyelid swelling with discoloration and patchy erythema and plagues on the face and abdominal wall.


Disclosure: Q. Yao, None; A. Kontzias, Novartis, 5.

To cite this abstract in AMA style:

Yao Q, Kontzias A. Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/expanding-the-phenotypic-and-genotypic-spectrum-in-yao-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expanding-the-phenotypic-and-genotypic-spectrum-in-yao-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology